LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Search

FibroGen Inc

Closed

SectorHealthcare

11.01 -5.9

Overview

Share price change

24h

Current

Min

10.64

Max

11.84

Key metrics

By Trading Economics

Income

-12M

-7.6M

Sales

-1.4M

1.3M

EPS

-1.88

Profit margin

-564.021

Employees

225

EBITDA

2.6M

-12M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+255.37% upside

Dividends

By Dow Jones

Next Earnings

11 lis 2025

Market Stats

By TradingEconomics

Market Cap

14M

48M

Previous open

16.91

Previous close

11.01

News Sentiment

By Acuity

100%

0%

360 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

FibroGen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 lut 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 lut 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Peer Comparison

Price change

FibroGen Inc Forecast

Price Target

By TipRanks

255.37% upside

12 Months Forecast

Average 43 USD  255.37%

High 43 USD

Low 43 USD

Based on 2 Wall Street analysts offering 12 month price targets forFibroGen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

0.306 / 0.33939Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

360 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat